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Some current bottlenecks
CCI is now getting some excellent papers. Part of Biomed
Central's policy – to which we fully subscribe – is that pa-
pers accepted following peer reviewing and revision to en-
sure the highest quality shall be published on our website
as quickly as possible, with free access worldwide. A turn-
around time of 50 days should now be well within the
norm, and may well fall to nearer 30–35 days. For excep-
tionally good papers, this time delay may be very much
shorter (technically it is possible to publish within a day),
and the mechanism is in place to achieve these remarka-
ble times. However, to date, CCI simply cannot boast an
improved turnaround time. Apart from some gremlins
that had to be sorted out in the publishing process for
niche journals, delay between submission and publica-
tion of good papers sadly remains much as for "conven-
tional" journals. The two main sticking points are (a) peer
reviewing and (b) author resubmission.
Taking the first, the rapid way in which a submitted paper
goes straight to a private website means that we direct ref-
erees attention to it almost instantly by emailing them the
private URL details. This is still a novelty for some review-
ers, who no longer have a hardcopy of the manuscript on
their desk as a constant reminder of the request made
upon them. We hope that, as everyone becomes more ac-
customed to handling email, reviewers will oblige us by
acknowledging receipt of the URL message and sending in
reports within 7 to 10 days.
On the other matter, it is not always clear to authors
where their responsibility lies in on-line publishing. The
most important thing is for an author to realise that he or she
is fully responsible for loading the manuscript in its entirety, in
complete conformity with the requirements laid down by BMC,
especially in file formats and style. Not only once, but at
times when the article is altered for any reason, it is the au-
thor's responsibility to resubmit the new version without delay.
We have no mechanism at present for reminding authors
that we await a new figure, table, or revised text file. We
simply believe that most changes that need to be made to
a manuscript can be done very quickly, and that authors
in their own interest will update their files at the earliest
opportunity; procrastination simply delays progress. It is
of little concern how many times this exercise is done be-
cause we always follow the latest version, although we
rather it was done just prior to final acceptance than at
every occasion when a comma is added or an excess space
deleted.
Submission charges
The Varmus Principle is that primary research papers
should be published online so that they become immedi-
ately and freely accessible to readers. Publication has its
costs, especially where extensive reviewing, editing and re-
vision has to be done to ensure that quality is not compro-
mised. But who pays? This issue has not been satisfactorily
resolved. No firm decision could have been taken, be-
cause the ways in which readers, writers, institutions, li-
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braries and funding agencies would react to either the
public or the private sector carrying out on-line publish-
ing were unknowns until we got the process firmly estab-
lished. An income stream is clearly necessary to sustain
the operation, which we now see as unlikely to be ade-
quately generated by advertising on our pages, or similar
ploys. It is recognised in all quarters, however, that the
"product" of research is a valid, creditable publication.
The final step, after all the research and writing up has
been done, is for the product to become readily available
(the prime function of any scientific or medical journal)
to the scientific and medical fraternities. Thus its produc-
tion should be seen as legitimate expenditure that comes
from the source of funding of the research that supported
the research in the first instance. Indeed, costing ought to
be automatically included in any grant application, al-
though a few agencies are still clearly unhappy that about
this. An alternative is that access to online websites is
made readily available from Institutions of Higher Learn-
ing to their employees and students. Many institutions
have therefore become affiliated to the online publishing
house, paying a subscription that allows any associate
working under their institutional umbrella to publish his
or her work without any further fee. For those remaining
outside these institutions, there will be a flat submission
fee of 500 US dollars. Where authors clearly find this dif-
ficult for economic reasons (as in third world countries)*,
the fee can be referred, reduced or waived, but where peo-
ple can pay, we hope that this once-only fee per manu-
script will be seen as an assured way of having the
privilege of publishing so that all your colleagues can get
free and immediate access to their work on their side, and
that we might be sufficiently well reimbursed to continue
in the future to provide this service to science. Sponsor-
ship might lighten this load off CCI, but we have to wait
to see whether philanthropy enters the online publishing
scene in the way it has supported libraries and other facil-
ities of higher learning in the past. To read more about
this, please go to Cancer Cell International's FAQ's pages
where the introduction and reasons for submission charg-
es are discussed  [http://www.cancerci.com/info/about/] .
* Please take careful note that there are ways in which less
privileged countries (a total of about 67) can gain subsi-
dies to assist in publication costs, provided the Varmus
principle is upheld. The Open Society Institute (OSI) in
Budapest controls funds made available through the gen-
erosity of the Soros Foundation, which allows authors
from countries such as Nigeria, Vietnam, Bulgaria, and 64
others to apply for help in getting manuscripts published.
We ask you to direct your attention to the controller of
this funding agency in Budapest, Ms Melissa Hagemann at
the following email address: mhagemann@sorosny.org
We ourselves are in negotiation with OSI, and through
them the process may be simplified by their providing di-
rect cover to us for the submission fees of manuscripts em-
anating from countries on their list.
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